Medivation (MDVN +0.75%) and not Dendreon (DNDN -3.5%) is the more attractive acquisition...
Medivation (MDVN +0.75%) and not Dendreon (DNDN -3.5%) is the more attractive acquisition target, says Jefferies analyst Biren Amin. This is because of the bright prospects for MDV3100, the prostate-cancer drug that Medivation half owns and the poor outlook for provenge, Dendreon's rival treatment.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 9:31AM)
at Zacks.com (Thu, 10:20AM)
at Investor's Business Daily (Thu, 9:56AM)
at Nasdaq.com (Jan 26, 2015)
at Nasdaq.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs